DexCom: The Beauty Of Open Architecture
Today the fight for the continuous glucose monitoring market isn’t so much about a large company and a mid-sized one battling for market share as about acceptance of the entire category of CGM, which remains low after more than a decade. DexCom believes that CGM should be a first-line blood glucose management tool to help diabetes patients keep their blood glucose levels within a healthy range, and now with the launch of a stellar fourth-generation product, the company is closer than ever to realizing that goal.
You may also be interested in...
The market for insulin delivery devices is positioned to change significantly with several manufacturers gearing their products toward type 2 diabetics, who make up 90% to 95% of the diabetes patient pool in the US. These new, “pump-like” devices could offer the type 2 diabetes population better control in managing glucose levels, a solution the medical community has been seeking for a while.
The director of the Scripps Translational Science Institute talks with “The Gray Sheet” about nano sensors, the move away from medical implants, and the role that established medical device companies can play in the burgeoning digital health field.
A Sept. 11 session on mHealth innovation at the American Telemedicine Association Fall Forum in New Orleans hosted experts representing the medical device industry, pharma, physicians, providers and patient activists.